OBI Pharma (ROCO:4174) Net Issuance of Preferred Stock : NT$0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

OBI Pharma's net issuance of preferred for the three months ended in Mar. 2025 was NT$0.00 Mil. The number is 0, which means that OBI Pharma has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

OBI Pharma's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was NT$0.00 Mil.

OBI Pharma Net Issuance of Preferred Stock Historical Data

The historical data trend for OBI Pharma's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Net Issuance of Preferred Stock Chart

OBI Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

OBI Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

OBI Pharma Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

OBI Pharma Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011

Website

https://www.obipharma.com

OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines